Clinical choices in managing LDL-c: Where do novel therapies fit in?

4 episodes

0.75 program credits

48m

Details

Episodes

Documents

Presenters

Comments

Overview
ASCVD develops throughout the life-course, indicating that there is a huge opportunity early in life to prevent the development or progression of the disease. In this series, four experts discuss why early initiation of lipid lowering therapies and LDL-c goal attainment is essential and address which options for LDL-c lowering beyond statins are currently available or in development. How well are we currently doing, which challenges are faced in clinical practice and what can be improved?
This course consists of 4 episodes. Watch all episodes, answer pre- and post-test questions, and start earning CME credits.
Program Highlights
This educational program consists of 4 presentations on LDL-c management.

The remaining challenges in lowering LDL-c in patients at increased CV risk- Kausik Ray, MD - London, UK
Kausik Ray addresses the challenges in the implementation of lipid lowering therapies (LLT) in patients at increased CV risk and discusses approaches to optimize LLT use.
Reaching LDL-c targets in patients at high CV risk: How well are we doing? - Julia Brandts, MD - Aachen, Germany
How well are we currently doing with LDL-c goal attainment in patients at increased CV risk? Julia Brandt summarizes key findings of recent registry studies.
The case for early LDL-c lowering in patients at increased CV risk: When should we start? - Pasquale Perrone-Filardi, MD, PhD - Naples, Italy
“The lower the better” and “the earlier the better”, says Pasquale Perrone-Filardi. He discusses recent real-world Italian data and imaging studies to support these statements.
Novel oral LDL-c lowering therapies on the horizon: CETP inhibition - Ulrich Laufs, MD, PhD - Leipzig, Germany
Which novel LDL-c lowering therapies are currently in development? Ulrich Laufs gives an overview, and focusses on CETP inhibition.
Instructions
- Watch the 4 lectures and answer the pre- and post-test questions
- Fill in the evaluation questions
- Download CME Certificate
For questions regarding this activity, please contact us at info@pace-cme.org.
Learning Objectives
After participating in this educational activity, participants should be better able to:
- Identify the challenges faced in clinical practice with LDL-C lowering
- Understand the unmet need for additional LDL-C-lowering therapies beyond current optimal statin-based therapy as a strategy for addressing lipid-related high cardiovascular risk  
- Discuss solutions for improving LDL-C goal attainment
- Discuss novel approaches for intensive lipid management in high-risk patients
- Recall outcomes of clinical trials with CETP inhibitors
Target Audience
This activity has been designed to meet the educational needs of cardiologists and internists as well as all other physicians, physician assistants, nurse practitioners, nurses, pharmacists, and healthcare providers involved in managing patients with elevated LDL-c.
Accreditation and Credit Designation Statements
This enduring activity is accredited by the European Board for Accreditation of Continuing Education for Health Professional (EBAC) for 48 minutes of effective education time.
Through an agreement between EBAC and the American Medical Association, physicians may convert EBAC External CME credits to AMA PRA Category 1 Credits™. Information on the process to convert EBAC credit to AMA credit can be found on the AMA website. Other health care professionals may obtain from the AMA a certificate of having participated in an activity eligible for conversion of credit to AMA PRA Category 1 Credit™.
Provider(s)/Educational Partner(s)
Today’s healthcare environment is constantly evolving and advances of medical science occur at an accelerating pace. CME/CE plays an important role in the clinical environment and is an essential element of physician training, learning, and improvement, thereby importantly contributing to optimal patient care. Since 2000, MEDCON’s mission is to deliver high quality within the world of medical education by creating forums like PACE-CME, organizing live meetings, and providing online education. We aim to stimulate the review, exchange, and assimilation of key scientific findings to improve patients’ health, to raise awareness of new science underlying various disease states, and to accelerate the translation of this information into clinical practice.
Commercial Support
Funding for this educational program was provided by an unrestricted educational grant from NewAmsterdam Pharma and Amgen.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of PACE-CME.
System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
  Apple Safari for Mac OS and iOS
  Mozilla Firefox for Windows, Mac OS, iOS, and Android
  Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date: 25/10/2024
Expiration Date: 25/10/2026